Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...
Test-Driving The 2025 Rolls-Royce Cullinan Series II
Rolls-Royce continues to defy logic with the luxurious Cullinan Series II, which improves the SUV's design while retaining ...
autoevolution2d
Can a Widebody Rolls-Royce Cullinan Be Elegant? Spoiler Alert: Heck Yes!
Despite the widebody makeover and new Vossen alloys, this pre-facelifted Rolls-Royce Cullinan is still very appealing. Dig ...
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...
Rolls-Royce CEO: Tariffs will have some impact on luxury goods, but don't weep for the luxury car maker
Rolls-Royce ( BMW.DE) CEO Chris Brownridge, like many other importers, is wary of President-elect Donald Trump's plans to ...
WMBD Peoria on MSN2d
Best Buy to leave Peoria; moving to The Levee District later this year
Best Buy will move out of its long time location in Peoria and move to The Levee District in East Peoria, Cullinan Properties ...
Yahoo Finance2d
Cullinan Therapeutics, Inc. (CGEM)
Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global ...
Tested: 2025 Rolls-Royce Cullinan Series II
The world's most opulent SUV has been given a refresh.